P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN

P1299 PEARL-III: 12 WEEKS OF ABT-450/R/267 + ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN P. Ferenci, A. Nyberg, P. Enayati, D. Bernstein, Y. Baruch, F.A. Caruntu, V. Chulanov, E. Janczewska, Z. Younes, R.T. Marinho, G. Rizzardini, J. Gervain, R. Planas, C. Moreno, W. Xie, D. Cohen, M. King, T. Podsadecki, K.R. Reddy. Universitaetsklinik fuer Innere Medizin III, Vienna, Austria; Kaiser Permanente, San Diego, California Liver Institute, Los Angeles, North Shore University Hospital, Manhasset, CA, United States; Rambam Health Care Campus, Haifa, Israel; Institutul National de Boli Infectioase ’Prof. Dr. Matei Bals’, Bucharest, Romania; Federal Budget Institute of Science Central Research Institute of Epidemiology, Moscow, Russian Federation; ID Clinic, Myslowice, Poland; GastroOne, Germantown, TN, United States; Centro Hospitalar Lisboa Norte, Lisboa, Portugal; Ospedale Luigi Sacco, Milano, Italy; Szent Gyorgy Hospital, Szekesfehervar, Hungary; Hospital Germans Tŕias i Pujol, CIBERehd, Badalona, Spain; CUB Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; AbbVie Inc., North Chicago, IL, University of Pennsylvania, Philadelphia, PA, United States E-mail: peter.ferenci@meduniwien.ac.at